Sign in Register

Readysharp Betamethasone (betamethasone acetate/betamethasone sodium phosphate)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Betamethasone is a synthetic glucocorticoid.

Betamethasone and its derivatives are used principally as anti-inflammatory or immunosuppressant agents. Because betamethasone has only minimal mineralocorticoid properties, the drug is inadequate alone for the management of adrenocortical insufficiency. If betamethasone is used in the treatment of this condition, concomitant therapy with a mineralocorticoid is also required.

Generic name: betamethasone acetate/betamethasone sodium phosphate
Pronunciation: (BAY-ta-METH-a-sone)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Readysharp Betamethasone

Intelligence content is not available yet.

Indications

The following indications are listed for Readysharp Betamethasone:

  • Acquired Thrombocytopenia
  • Acute Exacerbation Of Multiple Sclerosis
  • Acute Gouty Arthritis
  • Acute Lymphoid Leukemia
  • Acute Rheumatic Carditis
  • Adrenocortical Insufficiency
  • Adrenogenital Disorder
  • Angioedema
  • Ankylosing Spondylitis
  • Aspiration Pneumonitis
  • Atopic Dermatitis
  • Autoimmune Hemolytic Anemia
  • Berylliosis
  • Bursitis
  • Cerebral Edema
  • Contact Dermatitis
  • Crohn's Disease
  • Dermatitis Herpetiformis
  • Diamond Blackfan Anemia
  • Erythema Multiforme
  • Erythroblastic Anemia
  • Exfoliative Dermatitis
  • Hodgkin's Lymphoma
  • Humoral Hypercalcemia Of Malignancy
  • Hypersensitivity Drug Reaction
  • Idiopathic Thrombocytopenic Purpura
  • Inflammatory Bowel Disease
  • Juvenile Idiopathic Arthritis
  • Laryngeal Edema
  • Loffler Syndrome
  • Mycosis Fungoides
  • Nephrotic Syndrome
  • Non-Hodgkin's Lymphoma
  • Ocular Inflammation
  • Organ Transplant Rejection
  • Pemphigus
  • Post Traumatic Osteoarthritis
  • Psoriasis
  • Psoriatic Arthritis
  • Pure Red Cell Aplasia
  • Rheumatoid Arthritis
  • Sarcoidosis
  • Serum Sickness
  • Status Asthmaticus
  • Synovitis
  • Synovitis Due To Osteoarthritis
  • Systemic Dermatomyositis
  • Systemic Lupus Erythematosus
  • Tendonitis
  • Tenosynovitis
  • Thyroiditis
  • Transfusion Reaction Urticaria
  • Trichinosis
  • Ulcerative Colitis

Also known as: Aase Syndrome, Acquired Hemolytic Anemia Due To Antibodies, Acute Articular Gout, Acute Exacerbation Of Ms, Acute Gout Attack, Acute Gout Flare, Acute Lymphatic Leukemia, Acute Lymphocytic Leukemia, Acute Lymphogenous Leukemia, Acute Relapse Of Ms, Acute Relapse Of Multiple Sclerosis, Acute Severe Asthma, Acute Severe Asthma Attack, Acute Uratic Arthritis, Adrenal Cortical Hypofunction, Adrenal Failure, Adrenal Insufficiency, Adrenocortical Hypofunction, Adrenogenital Syndrome, Allergic Reaction To Blood Or Plasma, Allergic Transfusion Reaction, Anemia Lymphatica, Angioneurotic Edema, Arthritis Deformans, Arthrosis Deformans, Asthma With Status Asthmaticus, Atopic Eczema, Atrophedema, Axial Spondyloarthritis With Radiographic Sacroiliitis, Bannister's Disease, Bekhterev's Arthritis, Bekhterev's Disease, Bekhterev's Spondylitis, Besnier-Boeck-Schaumann Disease, Besnier-Boeck-Schaumann Syndrome, Blackfan Diamond Syndrome, Blistering Skin Disease, Boeck's Disease, Boeck's Sarcoid, Brain Edema, Bullous Dermatitis Herpetiformis, Colitis Ulcerativa, Congenital Erythroid Hypoplastic Anemia, Congenital Hypoplastic Anemia, Congenital Pure Red Cell Aplasia, Constitutional Erythroid Hypoplasia, Deficiency In Bone Marrow Erythroblasts, Dermatitis Venenata, Disseminated Lupus Erythematosus, Disseminated Neurodermatitis, Drug Hypersensitivity Reaction, Drug-Induced Hypersensitivity, Drug-Induced Hypersensitivity Reaction, Erythema Exfoliativa, Erythema Polymorphe, Erythroblastopenia, Erythroderma Exfoliativa, Erythrogenesis Imperfecta, Exfoliative Eczema, Exfoliative Erythroderma, Giant Urticaria, Hebra's Disease, Herpes Iris, Hodgkin's Disease, Hypercalcemia Associated With Cancer, Hypercalcemia Associated With Malignancy, Hypercalcemia Of Malignancy, Hypoadrenalism, Hypocorticoidism, Immune Thrombocytopenia, Immune Thrombocytopenia Purpura, Inflammation Of The Synovial Membrane, Inflammation Of The Synovium, Juvenile Ra, Juvenile Rheumatoid Arthritis, Loeffler Syndrome, Loffler's Syndrome, Lupus Erythematosus Syndrome, Lymphoblastic Leukemia, Malignant Hypercalcemia, Marie-Strumpell Disease, Marie-Strumpell Spondylitis, Mendelson's Syndrome, Milton's Disease, Multiple Sclerosis Exacerbation, Nodose Rheumatism, Non-Hodgkin's Type Lymphoma, Ophthalmic Inflammation, Organ Transplant Rejection Reaction, Periodic Urticaria, Pie Syndrome, Post Infectious Thrombocytopenia, Post Traumatic Oa, Post-Traumatic Osteoarthritis, Posttraumatic Osteoarthritis, Psoriasis Arthropica, Psoriatic Arthropathy, Purpura Hemorrhagica, Quincke's Disease, Quincke's Edema, Regional Enteritis, Regional Ileocolitis, Rheumatic Arthritis, Rheumatic Gout, Rheumatoid Spondylitis, Rhizomelic Spondylitis, Rhizomelic Spondylosis, Schaumann's Syndrome, Secondary Thrombocytopenia, Serum Sickness-Like Reaction, Severe Asthma Exacerbation, Simple Pulmonary Eosinophilia, Spondylosis Deformans, Strumpell-Marie Disease, Suprarenal Failure, Synovitis Due To Oa, Synovitis With Osteoarthritis, Tendinitis, Tendinous Synovitis, Tendosynovitis, Tendovaginitis, Tenontolemmitis, Tenontothecitis, Tenovaginitis, Transplant Rejection, Trichinella Spiralis Infection, Trichinellosis, Trichiniasis, Urticaria Tuberosa, Urticarial Transfusion Reaction, Werlhof's Disease.

Dosing

The route of administration and dosage of betamethasone and its derivatives depend on the condition being treated and the response of the patient. Dosage for infants and children should be based on the severity of the disease and the response of the patient rather than on strict adherence to the dosage indicated by age, body weight, or body surface area. After a satisfactory response is obtained, dosage should be decreased in small decrements to the lowest level that maintains an adequate clinical response, and the drug should be discontinued gradually as soon as possible. Lack of satisfactory response after a reasonable trial of betamethasone or betamethasone sodium phosphate in fixed combination with betamethasone acetate should lead to discontinuance of therapy and transfer to other appropriate therapy. Patients should be continually monitored for signs that indicate dosage adjustment is necessary, such as remissions or exacerbations of the disease and stress (surgery, infection, trauma). Following long-term therapy, betamethasone should be withdrawn gradually. (See the Corticosteroids General Statement 68:04.)

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data